PTC Therapeutics Inc (NASDAQ: PTCT) stock suffered a major decline of -11.8% on 6/28/24. The shares closed at $30.58. Moreover, exceptionally high trading volume at 329% of normal accompanied the decline. The stock has declined -8.1% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, PTCT is expected to be a major Value Eraser.
PTC Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment